A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma

PHASE2UnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2017

Conditions
Uveal Melanoma
Interventions
DRUG

Placebo

two tablets in the morning and two in the evening.

DRUG

Sorafenib

400 mg Sorafenib bid until PD if staging after Run-In was PR or CR

DRUG

Sorafenib

400 mg Sorafenib bid until PD if staging after Run-In was SD

Trial Locations (3)

12203

Universitätsmedizin Berlin, Charité Campus Benjamin Franklin, Berlin

45147

Univesitätsklinikum Essen, Essen

91052

Universitätsklinikum Erlangen, Erlangen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ClinAssess GmbH

INDUSTRY

lead

Prof. Dr. med. Max. E. Scheulen

OTHER

NCT01377025 - A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma | Biotech Hunter | Biotech Hunter